Deciphering an interplay of proteins associated with amyloid ß 1-42 peptide and molecular mechanisms of Alzheimer's disease

Reviews in the Neurosciences

Volumn 25, Issue 6, 2014, Pages 773-783

  Hernández Zimbrón, Luis Fernando ^a   Rivas Arancibia, Selva ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Alzheimer's disease; Amyloid beta; Protein interactions

Indexed keywords

ACETYLCHOLINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA SECRETASE; AMPA RECEPTOR; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CALCIUM; CELL PROTEIN; COLONY STIMULATING FACTOR 1; CYTOKINE; G PROTEIN COUPLED RECEPTOR; GAMMA SECRETASE; MITOCHONDRIAL ENZYME; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERVE GROWTH FACTOR; NEUROTROPHIN 3; NEUROTROPHIN 4; NEUROTROPHIN RECEPTOR P75; NICASTRIN; NICOTINIC RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PRESENILIN 1; PRESENILIN 2; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 9; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); AMYLOID PROTEIN; NERVE PROTEIN; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; ASTROCYTE; BRAIN MITOCHONDRION; BRAIN NERVE CELL; CALCIUM HOMEOSTASIS; CENTRAL NERVOUS SYSTEM; CHOLINERGIC NERVE CELL; CONFORMATIONAL TRANSITION; ENDOCYTOSIS; GLUCOSE METABOLISM; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATORY CELL; INTERNALIZATION; INTRACELLULAR TRANSPORT; MACROMOLECULE; MEMBRANE DAMAGE; MICROGLIA; MILD COGNITIVE IMPAIRMENT; NERVE CELL MEMBRANE; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; RESPIRATORY CHAIN; SENILE PLAQUE; SYNAPTIC TRANSMISSION; CHEMISTRY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN DOMAIN; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOIDOGENIC PROTEINS; HUMANS; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PROTEIN INTERACTION DOMAINS AND MOTIFS; SIGNAL TRANSDUCTION;

EID: 84925285435     PISSN: 03341763     EISSN: 21910200     Source Type: Journal    
DOI: 10.1515/revneuro-2014-0025     Document Type: Article

References (85)

1. Bamberger, M.E., Harris, M.E., McDonald, D.R., Husemann, J., and Landreth, G.E. (2003). A cell surface receptor complex for fibrillar â-amyloid mediates microglial activation. J. Neurosci. 23, 2665-2674.
2. Bi, X., Gall, C.M., Zhou, J., and Lynch, G. (2002). Uptake and pathogenic effects of amyloid â peptide 1-42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists. Neuroscience 112, 827-840.
3. Bobba, A., Amadoro, G., Valenti, D., Corsetti, V., Lassandro, R., and Atlante, A. (2013). Mitochondrial respiratory chain complexes I and IV are impaired by â-amyloid via direct interaction and through complex I-dependent ROS production, respectively. Mitochondrion 13, 298-311.
4. Bora, R.P. and Prabhakar, R. (2010). Elucidation of interactions of Alzheimer amyloid â peptides (Aâ40 and Aâ42) with insulin degrading enzyme: A molecular dynamics study. Biochem. 49, 3947-3956.
5. Bothwell, M. (1996). p75NTR: A receptor after all. Science 272, 506-507.
6. Cabrol, C., Huzarska, M.A., Dinolfo, D., Rodriguez, M.C., Reinstatler, L., Ni, J., Yeh, L.A., Cuny, G.D., Stein, R.L., Selkoe, D.J., et al. (2009). Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening. PLoS One 4, No. e5274.
7. Casley, C.S., Land, J.M., Sharpe, M.A., Clark, J.B., Duchen, M.R., and Canevari, L. (2002). â-Amyloid fragment 25-35 causes mitochondrial dysfunction in primary cortical neurons. Neurobiol. Dis. 10, 258-267.
8. Chavis, P. and Westbrook, G. (2001). Integrins mediate functional pre- and postsynaptic maturation at a hippocampal synapse. Nature 411, 317-321.
9. Chen, K., Iribarren, P., Hu, J., Chen, J., Gong, W., Cho, E.H., Lockett, S., Dunlop, N.M., and Wang, J.M. (2006). Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer diseaseassociated amyloid â peptide. J. Biol. Chem. 281, 3651-3659.
10. Christie, R.H., Freeman, M., and Hyman, B.T. (1996). Expression of the macrophage scavenger receptor, a multifunctional lipoprotein receptor, in microglia associated with senile plaques in Alzheimer's disease. Am. J. Pathol. 148, 399.
11. Connor, B., Young, D., Yan, Q., Faull, R.L.M., Synek, B., and Dragunow, M. (1997). Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Mol. Brain Res. 49, 71-81.
12. Coraci, I.S., Husemann, J., Berman, J.W., Hulette, C., Dufour, J.H., Campanella, G.K., and El Khoury, J.B. (2002). CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to â-amyloid fibrils. Am. J. Pathol. 160, 101-112.
13. Cramer, P.E., Cirrito, J.R., Wesson, D.W., Lee, C.D., Karlo, J.C., Zinn, A.E., and Landreth, G.E. (2012). ApoE-directed therapeutics rapidly clear â-amyloid and reverse deficits in AD mouse models. Science 335, 1503-1506.
14. Dineley, K.T., Bell, K.A., Bui, D., and Sweatt, J.D. (2002). Beta-amyloid peptide activates á7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J. Biol. Chem. 277, 25056-25061.
15. Du Yan, S., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996). RAGE and amyloid-Â peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691.
16. Duckworth, W.C., Bennett, R.G., and Hamel, F.G. (1998). Insulin degradation: Progress and potential 1. Endocr. Rev. 19, 608-624.
17. Dunah, A.W., Wyszynski, M., Martin, D.M., Sheng, M., and Standaert, D.G. (2000). á-Actinin-2 in rat striatum: Localization and interaction with NMDA glutamate receptor subunits. Mol. Brain. Res. 79, 77-87.
18. Dziewczapolski, G., Glogowski, C.M., Masliah, E., and Heinemann, S.F. (2009). Deletion of the á7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. J. Neurosci. 29, 8805-8815.
19. Eisenberg, D. and Jucker, M. (2012). The amyloid state of proteins in human diseases. Cell. 148, 1188-1203.
20. Ernfors, P. and Bramham, C.R. (2003). The coupling of a trkB tyrosine residue to LTP. Trends Neurosci. 26, 171-173.
21. Garzon, D.J. and Fahnestock, M. (2007). Oligomeric amyloid decreases basal levels of brainderived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J. Neurosci. 27, 2628-2635.
22. Geula, C. (1998). Abnormalities of neural circuitry in Alzheimer's disease hippocampus and cortical cholinergic innervation. Neurology 51, S18-S29.
23. Gevorkian, G., Gonzalez-Noriega, A., Acero, G., Ordoñez, J., Michalak, C., Munguia, M.E., and Manoutcharian, K. (2008). Amyloid-Â peptide binds to microtubule-associated protein 1B (MAP1B). Neurochem. Int. 52, 1030-1036.
24. Ghosh, C., Mukherjee, S., and Dey, S.G. (2013). Direct electron transfer between Cyt c and heme-Aâ relevant to Alzheimer's disease. Chem. Commun. 49, 5754-5756.
25. Gouras, G.K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J.P., Haroutunian, V., Buxbaum, J.D., Xu, H., et al. (2000). Intraneuronal Ab42 accumulation in human brain. Am. J. Pathol. 156, 15-20.
26. He, X.Y., Schulz, H., and Yang, S.Y. (1998). A human brain L-3-hydroxyacylcoenzymeA dehydrogenase is identical to an amyloid â-peptide-binding protein involved in Alzheimer's disease. J. Biol. Chem. 273, 10741-10746.
27. Hernández-Zimbrón, L.F., Luna-Muñoz, J., Mena, R., Vazquez-Ramirez, R., Kubli-Garfias, C., Cribbs, D.H., Manoutcharian, K., and Gevorkian, G. (2012). Amyloid-Â peptide binds to cytochrome C and oxidase subunit 1. PLoS One 7, e42344.
28. Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R.L., Atwood, C.S., and Smith, M.A. (2001). Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 21, 3017-3023.
29. Hoos, M.D., Ahmed, M., Smith, S.O., and Van Nostrand, W.E. (2007). Inhibition of familial cerebral amyloid angiopathy mutant amyloid â-protein fibril assembly by myelin basic protein. J. Biol. Chem. 282, 9952-9961.
30. In't Veld, B.A., Ruitenberg, A., Hofman, A., Launer, L.J., van Duijn, C.M., Stijnen, T., and Stricker, B.H. (2001). Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. New Engl. J. Med. 345, 1515-1521.
31. Inestrosa, N.C., Alvarez, A., Pérez, C., Moreno, R., Vicente, M., Linker, C., Casanueva, O., Soto, C., and Garrido J. (1996). Acetylcholinesterase accelerates assembly of amyloid-Â-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme. Neuron 16, 881-891.
32. Iqbal, K., del C Alonso, A., Chen, S., Chohan, M.O., El-Akkad, E., Gong, C.X., and Grundke-Iqbal, I. (2005). Tau pathology in Alzheimer disease and other tauopathies. BBA-Mol. Basis Dis. 1739, 198-210.
33. Iribarren, P., Chen, K., Hu, J., Gong, W., Cho, E.H., Lockett, S., and Wang, J.M. (2005). CpG-containing oligodeoxynucleotide promotes microglial cell uptake of amyloid â 1-42 peptide by up-regulating the expression of the G-protein-coupled receptor mFPR2. FASEB. J. 19, 2032-2034.
34. Jakovcevski, I., Filipovic, R., Mo, Z., Rakic, S., and Zecevic, N. (2009). Oligodendrocyte development and the onset of myelination in the human fetal brain. Front. Neuroanat. 3, 1-15.
35. Jeynes, B. and Provias, J. (2008). Evidence for altered LRP/RAGE expression in Alzheimer lesion pathogenesis. Curr. Alzheimer Res. 5, 432-437.
36. Jiang, Q., Lee, C.Y., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., and Landreth, G.E. (2008). ApoE promotes the proteolytic degradation of Aâ. Neuron 58, 681-693.
37. Kawai, T. and Akira, S. (2007). TLR signaling. Semin. Immunol. 19, 24-32.
38. Khan, G., Tong, M., Jhun, M., Arora, K., and Nichols, Y.R. (2010). â-Amyloid activates presynaptic á7 nicotinic acetylcholine receptors reconstituted into a model nerve cell system: Involvement of lipid rafts. Eur. J. Neurosci. 31, 788-796.
39. Kim, M., Hersh, L.B., Leissring, M.A., Ingelsson, M., Matsui, T., Farris, W., Lu, A., Hyman, B.T., Selkoe, D.J., Betram, L., et al. (2007). Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. J. Biol. Chem. 282, 7825-7832.
40. Koo, E.H., Lansbury, P.T., and Kelly, J.W. (1999). Amyloid diseases: Abnormal protein aggregation in neurodegeneration. Proc. Natl. Acad. Sci. USA 96, 9989-9990.
41. Kuner, P., Schubenel, R., Hertel, C. (1998). Amyloid binds to p75NTR and activates NFkB in human neuroblastoma cells, J. Neurosci. Res. 54, 798-804.
42. Kwong, J.Q., Henning, M.S., Starkov, A.A., and Manfredi, G. (2007). The mitochondrial respiratory chain is a modulator of apoptosis. J. Cell Biol. 179, 1163-1177.
43. La Ferla, F., Green, K., and Oddo, S. (2007). Intracellular amyloid-Â in Alzheimer's disease. Nat. Rev. Neu. 8, 499-509.
44. Lee, D.H. and Wang, H.Y. (2003). Differential physiologic responses of alpha7 nicotinic acetylcholine receptors to beta-amyloid1-40 and â-amyloid1-42. J. Neurobiol. 55, 25-30.
45. Lee, V.M., Goedert, M., and Trojanowski, J.Q. (2001). Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121-1159.
46. Liang, W.S., Reiman, E.M., Valla, J., Dunckley, T., Beach, T.G., Grover, A., and Stephan, D.A. (2008). Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc. Natl. Acad. Sci. USA 105, 4441-4446.
47. Li, Y., Liu, L., Barger, S.W., and Griffin, W.S.T. (2003). Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 23, 1605-1611.
48. Lin, B., Arai, A.C., Lynch, G., and Gall, C.M. (2003). Integrins regulate NMDA receptor-mediated synaptic currents. J. Neurophysiol. 89, 2874-2878.
49. Liu, Q., Kawai, H., and Berg, D.K. (2001). â-Amyloid peptide blocks the response of a7-containing nicotinic receptors on hippocampal neurons. Proc. Natl. Acad. Sci. USA 98, 4734-4739.
50. Lorenzo, A., Yuan, M., Zhang, Z., Paganetti, P.A., Sturchler- Pierrat, C., Staufenbiel, M., and Yankner, B.A. (2000). Amyloid â interacts with the amyloid precursor protein: A potential toxic mechanism in Alzheimer's disease. Nat. Neurosci. 3, 460-464.
51. Lustbader, J.W., Cirilli, M., and Lin, C. (2004). ABAD directly links amyloid beta to mitochondrial toxicity in Alzheimer's disease. Science 304, 448-452.
52. Malherbe, P., Richards, J.G., Gaillard, H., Thompson, A., Diener, C., Schuler, A., and Huber, G. (1999). cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Mol. Brain Res. 71, 159-170.
53. Morris, M.C., Evans, D.A., Bienias, J.L., Tangney, C.C., Bennett, D.A., Wilson, R.S., and Schneider, J. (2003). Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol. Chicago 60, 940-946.
54. McGeer, P.L., Rogers, J., and McGeer, E.G. (2006). Inflammation, anti-inflammatory agents and Alzheimer disease: The last 12 years. J. Alzheimers Dis. 9, 271-276.
55. Mucke, L., Masliah, E., Yu, G.Q., Mallory, M., Rockenstein, E.M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., and McConlogue, L. (2000). High-level neuronal expression of Aâ1- 42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J. Neurosci. 20, 4050-4058.
56. Mungarro-Menchaca, X., Ferrera, P., Morán, J., and Arias, C. (2002). â-Amyloid peptide induces ultrastructural changes in synaptosomes and potentiates mitochondrial dysfunction in the presence of ryanodine. J Neurosci. Res. 68, 89-96.
57. Munguia, M.E., Govezensky, T., Martinez, R., Manoutcharian, K., and Gevorkian, G. (2006). Identification of amyloid-beta 1-42 binding protein fragments by screening of a human brain cDNA library. Neurosci. Lett. 397, 79-82.
58. Nagahara, A.H., Merrill, D.A., Coppola, G., Tsukada, S., Schroeder, B.E., Shaked, G.M., Wang, L., Blesch, A., Kim, A., Conner, J.M., et al. (2009). Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat. Med. 15, 331-337.
59. Neant-Fery, M., Garcia-Ordoñez, R.D., Logan, T.P., Selkoe, D.J., Li, L., Reinstatler, L., and Leissring, M.A. (2008). Molecular basis for the thiol sensitivity of insulin-degrading enzyme. Proc. Natl. Acad. Sci. USA 105, 9582-9587.
60. Oz, M., Lorke, D.E., Yang, K.H., and Petroianu, G. (2013). On the interaction of â-amyloid peptides and á7-nicotinic acetylcholine receptors in Alzheimer's disease. Curr. Alzheimer Res. 10, 618-630.
61. Pahnke, J., Fröhlich, C., Krohn, M., Schumacher, T., and Paarmann K. (2013). Impaired mitochondrial energy production and ABC transporter function - A crucial interconnection in dementing proteopathies of the brain. Mech. Ageing Dev. 134, 506.
62. Panegyres, P.K. (2001). The functions of the amyloid precursor protein gene. Rev. Neurosci. 12, 1-40.
63. Peng, X., Katz, M., Gerzanich, V., Anand, R., and Lindstrom, J. (1994). Human á 7 acetylcholine receptor: Cloning of the á 7 subunit from the SH-SY5Y cell line and determination of pharmacological properties of native receptors and functional á 7 homomers expressed in Xenopus oocytes. Mol. Pharmacol. 45, 546-554.
64. Pérez, M., Cuadros, R., Benítez, M.J., and Jiménez, J.S. (2004). Interaction of Alzheimer's disease amyloid ß peptide fragment 25-35 with tau protein, and with a tau peptide containing the microtubule binding domain. J. Alzheimers Dis. 6, 461-467.
65. Pike, C.J., Walencewicz, A.J., Glabe, C.G., and Cotman, C.W. (1991). In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563, 311-314.
66. Poon, W.W., Blurton-Jones, M., Tu, C.H., Feinberg, L.M., Chabrier, M.A., Harris, J.W., and Cotman, C.W. (2011). â-Amyloid impairs axonal BDNF retrograde trafficking. Neurobiol. Aging 32, 821-833.
67. Puzzo, D., Privitera, L., Leznik, E., Fà, M., Staniszewski, A., Palmeri, A., and Arancio, O. (2008). Picomolar amyloid-Â positively modulates synaptic plasticity and memory in hippocampus. J. Neurosci. 28, 14537-14545.
68. Reddy, P.H. and Beal, M.F. (2008). Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer's disease. Trends Mol. Med. 14, 45-53.
69. Rees, T., Hammond, P.I., Soreq, H., Younkin, S., and Brimijoin, S. (2003). Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol. Aging 24, 777-787.
70. Sanan, D.A., Weisgraber, K.H., Russell, S.J., Mahley, R.W., Huang, D., Saunders, A., and Roses, A.D. (1994). Apolipoprotein E associates with â amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J. Clin. Invest. 94, 860.
71. Scheff, S.W., Price, D.A., Schmitt, F.A., DeKosky, S.T., and Mufson, E.J. (2007). Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68, 1501-1508.
72. Selkoe, D.J. (1999). Translating cell biology into therapeutic advances in Alzheimer's diseases. Nature 399, A23-A31.
73. Selkoe, D.J. (2001). Alzheimer's disease: Genes, proteins, and therapy. Physiol. Rev. 81, 741.
74. Small, D.H. and McLean, C.A. (1999). Alzheimer's disease and the amyloid â protein: What is the role of amyloid? J. Neurochem. 73, 443-449.
75. Smith G. (2007). The redox chemistry of the Alzheimer's disease amyloid peptide. Biochim. Biophys. Acta 1768, 1976-1990.
76. Stewart, W.F., Kawas, C., Corrada, M., and Metter, E.J. (1997). Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626-632.
77. Swerdlow, R.H., Burns, J.M., and Khan, S.M. (2010). The Alzheimer's disease mitochondrial cascade hypothesis. J. Alzheimers Dis. 20, 265-279.
78. Talaga, P. and Quere, L. (2002). The plasma membrane: A target and hurdle for the development of Anti-Aâ drugs? Curr. Drug Target C.N.S. Neurol. Disord. 1, 567-574.
79. Thathiah, A. and De Strooper, B. (2009). G Protein-coupled receptors, cholinergic dysfunction, and A {beta} toxicity in Alzheimer's Disease. Sci. Signal. 2, re8.
80. Wang, H.Y., Lee, D.H., D'Andrea, M.R., Peterson, P.A., Shank, R.P., and Reitz, A.B. (2000). â-Amyloid1-42 binds to á7 nicotinic acetylcholine receptor with high affinity. J. Biol. Chem. 275, 5626-5632.
81. Wang, H.Y., Li, W., Benedetti, N.J., and Lee, D.H. (2003). Alpha 7 nicotinic acetylcholine receptors mediate â-amyloid peptideinduced tau protein phosphorylation. J. Biol. Chem. 278, 31547-31553.
82. Wang, H.Y., Stucky, A., Liu, J., Shen, C., Trocme-Thibierge, C., and Morain, P. (2009). Dissociating â-amyloid from á7 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes á7 nicotinic acetylcholine and NMDA receptor function in Alzheimer's disease brain. J. Neurosci. 29, 10961-10973.
83. Yaar, M., Zhai, S., Pilch, P.F., Doyle, S.M., Eisenhauer, P.B., Fine, R.E., and Gilchrest, B.A. (1997). Binding of â-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. J. Clin. Invest. 100, 2333.
84. Yaar, M., Zhai, S., Fine, R.E., Eisenhauer, P.B., Arble, B.L., Stewart, K.B., and Gilchrest, B.A. (2002). Amyloid â binds trimers as well as monomers of the 75-kDa neurotrophin receptor and activates receptor signaling. J. Biol. Chem. 277, 7720-7725.
85. Yan, S.D. and Stern, D.M. (2005). Mitochondrial dysfunction and Alzheimer's disease: Role of amyloid â peptide alcohol dehydrogenase (ABAD). Int. J. Exp. Pathol. 86, 161-171.